Local prevention of EGFR inhibition in the skin might prevent or cure the skin rash caused by disruption of normal EGFR functions by the targeting therapeutics, without affecting anticancer activity, ensuring continuous treatment and, ultimately, clinical benefits. This evidence concerns the gene EGFR and exanthem.